HOME >> BIOLOGY >> NEWS
Breakthrough technology from Pall increases platelet availability and safety

East Hills, NY (October 5, 2005) -- Pall Corporation (NYSE: PLL) announced today FDA clearance to market the new Pall AcrodoseTM PL System. This is the first whole blood derived platelet system for pre-storage pooling and testing of leukoreduced whole blood derived platelets resulting in a transfusion-ready product for the hospital. This unique product increases the availability of lifesaving platelets, enhances patient safety and is more cost-effective for the hospital.

"Adequate platelet availability in some communities can sometimes be a challenge," says Allan Ross, President of Pall Medical. "The Acrodose PL System provides an opportunity for blood centers and hospitals to increase the availability of bacterially tested, leukoreduced, and pooled whole blood derived platelets in a cost-effective manner."

Platelets are derived from donors in either a one-to-two hour procedure called apheresis or from standard whole blood collections. Apheresed platelets are limited by donor availability. They are also time consuming and capital intensive to obtain. Regardless of which collection process is used, bacterial contamination of platelets is the leading infectious cause of illness and death from a blood transfusion. Single donor platelets are tested for bacterial contamination using a sensitive culture detection method such as Pall's eBDS, enhanced bacterial system. Whole blood derived platelet units on the other hand are tested using less sensitive methods due to cost, product loss, and logistical constraints of testing several individual units to obtain a standard therapeutic dose. This has resulted in a disparity of test sensitivities as well as underutilization of a valuable blood resource.

The new Acrodose PL System enables blood centers to pool individual whole blood derived platelets prior to storage and conduct a single bacterial contamination test with its integrated Pall eBDS technology. Studies using the Pall eBDS System with pooled p
'"/>

Contact: Marcia Katz
marcia_katz@pall.com
516-801-9128
Pall Corporation
6-Oct-2005


Page: 1 2

Related biology news :

1. Breakthrough developments in rheumatoid arthritis reported
2. Breakthrough for treatment of fatal heart condition
3. Breakthrough vaccine to treat chemo-resistant ovarian cancer
4. Breakthrough in understanding type 2 diabetes as key genes identified
5. Breakthrough in nanodevice synthesis revolutionizes biological sensors
6. Breakthrough for future exploration unrecoverable gas reserves
7. Breakthrough by MUHC researcher has major implications
8. Breakthrough offers new tool for studying degenerative disease
9. Breakthrough in brain injury study at University of Leicester
10. Breakthrough for stem cell research
11. Sciences Breakthrough of the Year: Watching evolution in action

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017   Biostage, Inc. ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, announced today the closing on February ... 20,000,000 shares of common stock and warrants to purchase ... of $8.0 million. The offering was priced at $0.40 ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced ... professor and Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at ... practicing female physician suffering from degenerative disc disease with radiculomyelopathy, as a result ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, Slone ... with GenePeeks. Matt is a veteran life sciences and molecular diagnostics executive ... focused on identifying inherited disease risk in future generations. In his new role, ...
(Date:2/15/2017)... , Feb. 15, 2017 Windtree Therapeutics, ... company focused on developing aerosolized KL4 surfactant therapies ... completed a $10.5 million private placement of convertible ... has sufficient capital to fund its operations through ... data release in mid-2017. Windtree has ...
Breaking Biology Technology:
Cached News: